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ORIGINAL ARTICLE
Introduction: Most non–small-cell lung cancer tumors with epider-
mal growth factor receptor mutations are responsive to EGFR tyro-
sine kinase inhibitors, such as gefitinib and erlotinib, but almost all 
such tumors ultimately acquire resistance. We previously found that 
a gefitinib-resistant cell line, PC-9/Met in which MET (MNNG-HOS 
transforming gene) is amplified, was more sensitive than its par-
ent cell line (PC-9) to 7-ethyl-10-hydroxy-camptothecin (SN-38), 
an active metabolite of irinotecan. The purpose of this study was to 
investigate the mechanisms responsible for the increased sensitivity of 
the gefitinib-resistant cell line to SN-38.
Methods: The sensitivity of PC-9 and PC-9/Met to SN-38 was 
assessed by performing water soluble tetrazolium salt (WST-1) 
assays. Topoisomerase I (topo I) activities were determined for the 
cell lines cultured in the presence of hepatocyte growth factor and for 
those of which MET expression was knocked down by introducing a 
MET-specific small interfering RNA.
Results: PC-9/Met exhibited higher topo I activities, and higher topo 
I gene and protein expression levels than PC-9 did. Suppression of 
MET expression by a MET-specific small interfering RNA led to 
a decrease in the topo I protein expression in the PC-9/Met cells. 
The stimulation of PC-9 with hepatocyte growth factor caused an 
increase in the topo I protein level via the activation of MET.
Conclusions: The increased sensitivity of PC-9/Met cells to SN-38 
compared with that of PC-9 cells was partially because of  topo I 
activities resulting from increased topo I mRNA and protein expres-
sion  caused by MET signaling.
Key Words: Topoisomerase I, MET, Epidermal growth factor receptor-
tyrosine kinase inhibitors resistance.
(J Thorac Oncol. 2012;7: 1337–1344)
The epidermal growth factor receptor (EGFR) is frequently expressed in non–small-cell lung cancer (NSCLC), and 
elevated EGFR levels are associated with advanced-stage 
disease, resistance to platinum-based chemotherapy, and a 
shorter survival time.1–4 EGFR tyrosine kinase inhibitors 
(EGFR-TKIs) have a significant impact in NSCLC patients 
with EGFR mutations.5–7 Several prospective trials have 
shown that the tumor response rates to gefitinib therapy are 
approximately 75% in the patients with tumors harboring 
EGFR mutations.8–12 Nevertheless, despite the initial dra-
matic tumor shrinkage, the tumors of most patients thereafter 
become resistant to EGFR-TKIs and eventually relapse.
Several mechanisms of acquired resistance to EGFR-
TKIs have recently been reported, including a secondary point 
mutation that substitutes metionine for threonine at position 
790 (T790M) in EGFR, and an amplification of the MET 
proto-oncogene, which are expressed in 44% to 50% and 22% 
of the patients, respectively.13–15 Ongoing preclinical and clini-
cal studies have suggested that irreversible EGFR-TKIs over-
come the resistance because of the T790M mutation, and that 
treatment with MET inhibitors, such as MET-TKI, could over-
come the resistance because of MET amplification.16–19 The 
efficacy of cytotoxic agents after the development of resis-
tance to EGFR-TKI is uncertain.
7-ethyl-10-hydroxy-camptothecin (SN-38), an active 
metabolite of irinotecan, has been demonstrated to have a broad 
spectrum of activity against mammalian cancer cells including 
NSCLC cells, small-cell lung cancer cells, and colorectal cancer 
cells.20–23 SN-38 prevents the religation of breaks in single-DNA 
strands by stabilizing the strands in a DNA-topoisomerase I 
(topo I) “cleavable complex.” SN-38 induces DNA damage 
and transient S-phase arrest, and these interactions have lasting 
effects that are correlated with its cytotoxic activity.23 Topo I 
activity is important for the initiation and elongation during 
DNA synthesis.24 It has been found that the topo I expression 
level and activity are positively correlated with the cytotoxicity 
of topo I inhibitors both in vitro and in vivo.25–28
The purpose of the present study was to investigate 
the sensitivity of a gefitinib-resistant cell line, PC-9/Met, to 
SN-38, and to investigate the mechanism underlying the col-
lateral sensitivity to SN-38 in PC-9/Met cells. In particular, 
we investigated whether the hepatocyte growth factor (HGF)/
MET signaling pathway can regulate the topo I status.Copyright © 2012 by the International Association for the Study of Lung Cancer
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MATERIALS AND METHODS
Drug Formulation and Administration
Gefitinib [N-(3-chloro-4-fluorophenyl)-7-methoxy-6-
(3-{morpholin-4-yl}propoxy)quinazolin-4-amine], cisplatin, 
etoposide, vincristine, and SN-38 were purchased from 
Toronto Research Chemicals Inc. (North York, Canada). Both 
drugs were dissolved in DMSO for use in the in vitro study.
Cell Lines and Cell Culture
The human NSCLC cell line PC-9, which was derived 
from a previously untreated adenocarcinoma patient, was pro-
vided by Professor K. Hayata (Tokyo Medical College, Tokyo, 
Japan). PC-9 is a gefitinib-sensitive cell line, and we devel-
oped the gefitinib-resistant PC-9/Met subline by continuously 
culturing PC-9 cells in gefitinib and gradually increasing the 
concentration of the drug in the medium over a period of 1 
year.29 Resistance to gefitinib was confirmed after culture in 
gefitinib-free conditions for 6 months. We demonstrated MET 
amplification in the surviving cells that were cloned during 
gefitinib exposure, and named the subline PC-9/Met. It was 
confirmed that the PC-9 and PC-9/Met cells were the same 
as the parental cells (PC-9) by a short tandem repeat–poly-
merase chain reaction (PCR) analysis (Supplementary Data 
1, Supplemental Digital Content 1, http://links.lww.com/JTO/
A302). Both cell lines were maintained in RPMI medium 
1640 (Invitrogen, Grand Island, NY) supplemented with 10% 
fetal bovine serum (FBS; Invitrogen) in an incubator at 37°C 
in a less-than 5% carbon dioxide atmosphere.
Growth Inhibition Assay
We used the water soluble tetrazolium salt (WST-1) 
assay (Cell Proliferation Reagent WST-1; Roche, Tokyo, 
Japan) to evaluate the cytotoxicity of various concentrations 
of the drugs. A 180-μl volume of a growing cell suspension 
(2 × 103 cells/well) was seeded into each well of a 96-well 
microtiter plate, and a 20-μl volume of a solution of each drug 
at various concentrations was added to each well. After incu-
bation for 72 hours at 37°C in less-than 5% carbon dioxide 
atmosphere, 10 μl of WST-1 solution was added to each well, 
and the plates were incubated at 37°C for an additional 90 
minutes. The absorbance of these samples was then measured 
at 450 nm with a microplate enzyme-linked immunosorbent 
assay reader (Thermo Labosystems, Multiskan JX, Osaka, 
Japan). Each experiment was carried out independently in 
triplicate. The IC
50
 value was defined as the concentration 
required to reduce the absorbance by 50%, and was calculated 
based on the survival curves for the assessment of growth 
inhibition.
Preparation of Nuclear Lysates and  
Whole-Cell Lysates
Nuclear lysates were prepared by using NE-PER nuclear 
and cytoplasmic extraction reagents (Thermo Scientific, 
Rockford, IL), and whole-cell lysates were prepared using M-PER 
mammalian protein extraction reagents (PIERCE, Rockford, IL). 
The protein concentrations were determined using the BCA pro-
tein assay reagent (Thermo Scientific).
Fluorescence In Situ Hybridization Analyses
All the PC-9 and PC-9/Met cells that were cultured with 
10% FBS were trypsinized. The cell suspension was centri-
fuged at 1200 rpm for 5 minutes and the pellet was washed 
two times with phosphate-buffered saline. An unstained slide 
was made for each cell pellet, and the pellet was subjected to 
dual color fluorescence in situ hybridization assays using a 
MET/chromosome 7 centromere (CEP7) probe labeled with 
SpectrumRed and SpectrumGreen CEP7 (Abbott Molecular 
Inc., Des Plaines, IL) according to the manufacturer’s instruc-
tions. The total number of red and green signals counted in the 
tumor nuclei was recorded, and then ratio of the MET (red) to 
CEP7 (green) signals for a total of 20 tumor nuclei was calcu-
lated. The cells with a MET:CEP7 ratio greater than 2.0 were 
considered to have MET amplification.
Topoisomerase I Activity Assay
After adjusting the protein concentrations, the topo I 
activity was measured by DNA relaxation assays that were 
performed using a topoisomerase assay kit (TopoGEN, Inc., 
Florida, CA;) according to the manufacturer’s instructions.30,31 
The DNA was stained with ethidium bromide, and the bands 
were visualized by UV transillumination.
Western Blot Analysis
A 20-μl volume of protein per lane was loaded on 4% 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis 
gels (Bio-Rad, Tokyo, Japan) and run at a constant current 
of 90 mV for 80 minutes. The proteins were transferred onto 
polyvinylidene fluoride microporous membranes (Millipore, 
Bedford, MA) by electroblotting at a constant current of 190 
mA for 80 minutes. The membranes were then blocked by 
immersion for at least 1 hour in 5% milk (nonfat powdered 
milk) buffered with Tris-buffered saline. Next, the membranes 
were incubated overnight with a primary antibody suspended 
in 5% buffered milk at an adequate dilution. After washing 
three times with  Tris-buffered saline, the membranes were 
exposed to horseradish peroxidase–labeled secondary 
antibodies and probed with rabbit polyclonal antibodies 
against EGFR, phospho-EGFR, Akt, phospho-Akt, Erk 
phosphor-Erk (Cell Signaling, Beverly, MA), and with a 
monoclonal antibody against topo I (TopoGEN, Inc., Port 
Orange, FL). Specific signals were visualized by using the 
ECL Plus Western Blotting Detection System (GE Healthcare 
UK Ltd., Amersham, UK). The intensities of the blots for 
topo I expression were quantified using the Image J software 
(version 1.45; National Institutes of Health, Bethesda, MD).
Quantitative Reverse Transcription-PCR for the 
Expression of Topo I mRNA
Total cellular RNA was extracted with the ISOGEN 
reagents (Nippon Gene, Tokyo, Japan). The quantity of 
total RNA was measured using a NanoDrop ND1000 fluo-
rospectrometer (NanoDrop Technologies, Tokyo, Japan). 
cDNA was synthesized from 500 ng of deoxyribonu-
clease-treated RNA by using a random hexamer primer. 
To measure the topo I mRNA expression, quantitative 
reverse transcription-PCR was performed on a LightCycler 
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(Roche, Tokyo, Japan). The topo I expression levels were 
determined by using SYBR premix Ex Taq II perfect 
real-time reagents (Takara, Shiga, Japan) and the prim-
ers 5′-CAATGGCCCAGGCAAACTTC-3′ (forward) and 
5′-AAGTTCAAGCCACAGACCGAGAG-3′ (reverse) under 
cycling parameters that consisted of one cycle of 98°C for 
2 minutes; 30 cycles of 98°C for 10 seconds, 58°C for 30 
seconds, and 72°C for 14 seconds; and followed by one cycle 
of 72°C for 5 minutes. The amplification of β
2
 microglobulin 
was used for normalization. The relative topo I expression 
levels were calculated by the delta-delta method.32,33
Transfection and Small Interfering RNA 
Experiments
PC-9 and PC-9/Met cells were seeded in six well cul-
ture dishes at a density of 5 × 104 cells/well and allowed to 
grow overnight in RPMI 1640 medium containing 10% 
FBS. The cells were transfected with small interfering RNA 
(siRNA) against MET or with scrambled RNA by using 
Lipofectamine 2000 (Invitrogen) in accordance with the 
manufacturer’s instructions. The sequence of the siRNA was: 
MET, 5′-UGAAUUAGGAAACUGAUCUUCUGGA-3′ and 
5′-UCCAGAAGAUCAGUUUCCUAAUUCA-3′. After incu-
bation for 24 hours, the cells were washed with fresh medium 
and incubated for an additional 48 hours, and the cell lysates 
were then prepared from the cultured cells for the detection of 
MET expression.
Stimulation of PC-9 and PC-9/Met With HGF
PC-9 and PC-9/Met cells were seeded in cell culture plates 
at a density of 1 × 105 cells/well, and were starved overnight in 
RPMI 1640 medium containing 0.1% FBS. The cells were then 
incubated with 20 ng/ml of recombinant HGF (R&D Systems, 
Minneapolis, MN). Whole-cell proteins were extracted from the 
cells at 30 minutes and 60 minutes, whereas nuclear proteins 
were extracted at 6 hours, 12 hours, and 24 hours after treatment, 
respectively. In the sensitivity test, the tumor cells were incubated 
with 0.1% FBS with RPMI 1640 medium overnight, then 20 ng/
ml of HGF was added to the cell suspensions. The drug exposure 
for 24 hours was chosen because the cell viabilities under starva-
tion conditions were too low for longer periods of time.
Statistical Analysis
All data are expressed as the means ± SD and were ana-
lyzed by Student’s t test. p values less than 0.05 were consid-
ered to be evidence of statistical significance. All statistical 
analyses were performed by using the Stat Mate IV (ATMS, 
Tokyo, Japan) software program.
RESULTS
The Growth Inhibitory Effects of Gefitinib and 
SN-38 on PC-9 and PC-9/Met Cells
We first evaluated the sensitivities of the PC-9 and gefi-
tinib-resistant PC-9/Met cells. The IC
50
 values for gefitinib in 
these cells were 0.088 ± 0.014 μM and 10.3 ± 5.0 μM, respec-
tively (Fig. 1), confirming that the PC-9/Met cells are resistant 
FIGURE 1. The sensitivity of PC-9 and gefitinib-resistant PC-9/Met cells to gefitinib and SN-38. The cells (2 × 103 cells/well) 
were seeded on 96-well plates, and after preincubation for 24 hours were exposed to various concentrations of each drug. After 
incubation for 72 hours, the growth inhibition rate was analyzed by a WST-1 assay as described in the Materials and Methods 
section. The points represent the means of the data generated from at least three experiments performed in triplicate. Bars, SD. 
PC-9 cells, PC-9/Met cells. SN-38, 7-ethyl-10-hydroxy-camptothecin.
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to gefitinib. The IC
50
 values for SN-38 in the PC-9 and PC-9/
Met cells were 0.093 ± 0.049 μM and 0.027 ± 0.014 μM, 
respectively, showing that PC-9/Met cells are more sensitive 
than their parental PC-9 cells to SN-38. PC-9/Met cells were 
equally sensitive to cisplatin and etoposide. Nevertheless, 
the PC-9/Met cells exhibited a 12-fold decreased sensitivity 
to vincristine (Supplementary Data 2, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A303).
Characterization of PC-9 and PC-9/Met Cells
We examined the protein expression levels of the 
PC-9 and PC-9/Met cells (Fig. 2A). As expected, a Western 
blot analysis revealed higher expression of the MET protein 
in the PC-9/Met cells than in the PC-9 cells. The MET 
phosphorylation in PC-9/Met cells was also higher than 
that in the PC-9 cells. We confirmed that there was MET 
gene amplification in PC-9/Met cells by a fluorescence in 
situ hybridization analysis (Fig. 2B). The EGFR protein 
expression and EGFR phosphorylation levels in the PC-9/Met 
cells were lower than those in the PC-9 cells. In each cell line, 
gefitinib treatment did not affect the protein expression and 
phospholylation of MET or topo I (data not shown).
PC-9/Met Cells Have Higher Topo I Activity, 
and Increased Topo I mRNA and Protein 
Expression Levels Compared With PC-9 Cells
Our results showed that the topo I expression level in 
the PC-9/Met cells was significantly higher than that in the 
PC-9 cells (Fig. 2A). We then examined the topo I activity in 
each cell line, and found that the activity in PC-9/Met cells 
was approximately fourfold higher compared with that in the 
PC-9 cells (Fig. 2C). The topo I mRNA level of the PC-9/Met 
FIGURE 2. A, A comparison of the protein expression levels of topo I, MET, p-MET, EGFR, p-EGFR, Akt, and p-Akt in the PC-9 
and PC-9/Met cells as determined by a Western blot analysis. Topo I migrated to approximately the 70 kDa position. The data 
are expressed as the means ± SD from more than three experiments. *p < 0.05. B. The MET gene amplification status in the 
PC-9 and PC-9/Met cells was determined by a fluorescence in situ hybridization analysis. The chromosome 7 centromere signals 
are green, and the MET signals are red. MET amplification was found in the PC-9/Met cells, but not in the PC-9 cells. C, Topo I 
activity in the PC-9 cells, and the gefitinib-resistant PC-9/Met cells. Complete activity is seen when no supercoiled DNA sub-
strate remains, and the presence of some supercoiled DNA indicates partial activity. The upper bands are attributable to DNA 
nicking by contaminating nucleases. The bottom band, indicated by the arrow, represents supercoiled DNA degraded by topo I.  
The topo I activity was normalized to the amount of nuclear protein extracted, such as 1.8 μg, 0.9 μg, 0.45 μg, and 0.225 μg, 
respectively, in both cell lines. In the PC-9/Met cells, the band of supercoiled DNA was eliminated when 0.9 μg of nuclear pro-
tein was added to the reaction mixture. However, the band of supercoiled DNA remained when 1.8 μg of nuclear protein from 
the PC-9 cells was added. These results showed that the topo I activity of the PC-9/Met cells was approximately fourfold higher 
than that of the PC-9 cells. D, Measurement of the topo I mRNA expression in PC-9 and PC-9/Met cells as determined by real-
time PCR. The topo I mRNA level of the PC-9/Met cells was approximately 9.2 times higher than that of the PC-9 cells. EGFR, 
epidermal growth receptor factor; p-EFGR, phospho-EGFR; p-Akt, phospho-Akt; p-MET, phospho-MET; topo I, topoisomerase I; 
mRNA, messenger RNA; PCR, polymerase chain reaction.
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cells was approximately 9.2 times higher than that of the PC-9 
cells (Fig. 2D).
Knockdown of MET Expression Decreased the 
Sensitivity of Cells to SN-38 by Reducing the 
Topo I Activity and Protein Expression Level
The most remarkable feature of the PC-9/Met cells 
compared with the PC-9 cells was their strong expression of 
MET and phosphorylation of MET. Therefore, to elucidate 
the mechanism underlying the high sensitivity of the PC-9/
Met cells to SN-38, we focused on the relationship between 
MET signaling and topo I, and investigated whether knocking 
down MET expression in PC-9/Met cells would alter the topo I 
expression and activity. Knocking down MET expression in the 
PC-9 and PC-9/Met cells using a MET-specific siRNA resulted 
in down-regulation of the topo I protein expression level and 
topo I activity in PC-9/Met cells (Fig. 3A–C). However, the 
topo I expression in the PC-9 cells was not affected by the 
knockdown of MET (Fig. 3A). We have also examined the 
kinetics of topo I expression after the treatment with MET 
siRNA, and confirmed that the PC-9 -cells were not affected 
(Fig. 3B, and Supplementary Data 3, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A304). The results of 
the WST cytotoxicity assays showed that the PC-9/Met cells 
treated with MET-specific siRNA were less sensitive to SN-38 
than the PC-9/Met cells transfected with scrambled RNA were 
(Fig. 3D). Neverthless, the sensitivity of the PC-9/Met cells 
treated with the MET-specific siRNA was still higher than that 
of the PC-9 cells. In contrast, the sensitivities to these non-
topo I–targeted drugs (cisplatin, etoposide, and vincristine) 
were not affected by knockdown of MET in either the PC-9 or 
PC-9/Met cells (Supplementary Data 4, Supplemental Digital 
Content 4, http://links.lww.com/JTO/A305). We also examined 
whether topo I expression was down-regulated when EGFR 
was knocked down. We found that the topo I expression was 
not affected by the knockdown of the EGFR in either PC-9 or 
PC-9/Met cells (Supplementary Data 5, Supplemental Digital 
Content 5, http://links.lww.com/JTO/A306).
HGF Increased the Topo I Activity, Topo I 
Protein Expression, and Sensitivity to SN-38
As our results suggested that a relationship existed 
between HGF/MET signaling and the topo I status, we fur-
ther investigated whether HGF stimulation would increase 
the level of topo I protein expression in the two cell lines. 
After HGF stimulation for 60 minutes, the phosphorylation of 
MET was induced, and after HGF stimulation for 6 hours, 12 
hours, and 24 hours, the topo I expression was up- regulated 
in both cell lines (Fig. 4A, B). The increase in the topo I level 
in response to HGF stimulation was significantly higher in 
the PC-9 cells than in the PC-9/Met cells. We next investi-
gated whether HGF increased the sensitivity to SN-38 in the 
two cell lines. To exclude the effects of stimulation with other 
ligands, the cells were cultured overnight  in RPMI supple-
mented with 0.1% FBS under starvation conditions. HGF (20 
ng/ml) was then added, and the cells were exposed to SN-38 
for 24 hours. Under these conditions, the viability of the PC-9 
and PC-9/Met cells was decreased by exposure to SN-38 in 
a concentration-dependent manner. The sensitivity of PC-9/
Met cells was also higher than that of the PC-9 cells cultured 
under starvation conditions. HGF stimulations increased in 
the sensitivity of both the PC-9 and PC-9/Met cells to SN-38 
(Fig. 4B). Although the sensitivity to SN-38 was observed to 
increase in both cell lines, the PC-9/Met cells without HGF 
stimulation were still more sensitive than the PC-9 cells sub-
jected to HGF stimulation.
DISCUSSION
This study focused on an acquired EGFR-TKI resistant cell 
line in which MET was amplified. There were two major findings 
of this study. The first was that a gefitinib-resistant cell line, PC-9/
Met, has collateral sensitivity to SN-38, a topo I inhibitor, as a 
result of an increase in topo I activity. The second major finding 
was that topo I activity is regulated via MET signaling.
Okabe et al.34 showed that the addition of S-1 to an 
EGFR-TKI inhibited the growth of gefitinib-resistant NSCLC 
with MET amplification by down-regulating thymidylate syn-
thase and the transcription factor E2F-1. A combination of S-1 
or SN-38 with an EGFR-TKI also might exert a possible syn-
ergistic effect. A phase I/II study showed that a combination 
of irinotecan and gefitinib was effective in NSCLC patients 
with gefitinib failure.35 Although MET amplification was not 
measured in that study, there is a possibility that MET ampli-
fication in the resistant tumors might have made them more 
sensitive to this combination. An in vivo study by Shimoyama 
et al.36 showed the efficacy of a sequential combination of iri-
notecan and gefitinib in a gefitinib-resistant cell line in which 
the mechanism of resistance was not reported. The results of 
our present study indicate that topo I inhibitors, such as iri-
notecan, might be useful agents for overcoming EGFR-TKI 
resistance that is mediated by MET amplification.
In our study, PC-9/Met cells showed collateral sensitivity 
to SN-38 compared with PC-9 cells. To confirm the collateral 
sensitivity to SN-38 in these cells, we examined the topo I 
mRNA expression, protein expression, and activity levels in each 
cell line. In PC-9/Met cells, the mRNA and protein expression, 
and the activity of topo I were higher than in the PC-9 cells. The 
results of the topo I activity assays performed in this study are 
consistent with previous studies showing that the sensitivity to 
topo I inhibitors correlates with the topo I activity of the tumor 
cells.25–28 We next examined the effects of MET-specific siRNA or 
MET stimulation by HGF on the topo I level in these experiments. 
The knockdown of MET resulted in the down-regulation of topo 
I, and HGF stimulation resulted in the up-regulation of topo I in 
both cell lines. Finally, we examined the sensitivity of the cells to 
SN-38 after treatment with a MET-specific siRNA or HGF. Down-
regulation of the MET amplification in the PC-9/Met cells treated 
with MET-specific siRNA led to a decrease in their sensitivity to 
SN-38. However, these cells were still more sensitive than the 
PC-9 cells without siRNA treatment (Fig. 3D). The sensitivity 
to SN-38 increased when both cell lines were treated with HGF, 
but the sensitivity of the PC-9 cells stimulated by HGF was still 
lower than that of the PC-9/Met cells without stimulation. These 
results suggest that the topo I activity of these cells was partially 
regulated by HGF-MET signaling.
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This is the first report to provide evidence that MET 
signaling plays a role in regulating topo I activity. MET, a 
high affinity tyrosine kinase receptor for HGF, is a disulfide-
linked heterodimer composed of a 45-kDa α-subunit and 
a 145-kDa β-subunit.37,38 When MET is activated by HGF, 
it transduces strong signals to various pathways, including 
the phosphatidylinositol 3-kinases/Akt pathway.39,40 HGF 
and c-Met have been found to be frequently overexpressed 
in many types of human solid tumors41–44 and in associated 
metastases, and the degree of MET expression correlates 
with the patients’ survival.45 Our data led us to hypothesize 
that treatment strategies that target topo I may therefore 
be effective against tumors with enhanced MET signaling. 
However, as no factors that regulate topo I have ever been 
identified, the relationship between HGF/MET and topo 
I is unclear. To support our findings, it will be necessary 
to identify the link between topo I activity and MET sig-
naling. Further studies are called for to shed light on the 
mechanism(s) underlying the regulation of topo I activity 
by MET signaling.
FIGURE 3.  Specific down-regulation of MET affects the level of topo I protein expression and the enzyme activity, while also 
decreasing the sensitivity of cells to SN-38. Control and MET-specific siRNA were introduced into the PC-9 and PC-9/Met cell 
lines. A. Whole-cell proteins and nuclear proteins were extracted 48 hours later, and a Western blot analysis was performed.  
To detect the MET protein, a 20-μg protein sample was loaded per lane for the PC-9 cells and PC-9/Met cells. To measure topo 
I protein expression, 10-μg samples of nuclear protein were loaded for both the PC-9 and PC-9/Met cell lines. The data are 
expressed as the means ± SD from more than three experiments, *p < 0.05 versus control. B. The relationship between topo I 
expression and MET expression by a Western blotting analysis at 0 hour, 6 hours, 12 hours, and 24 hours after siRNA addition. 
C, The effect of the specific down-regulation of MET on the topo I activity of the PC-9/Met cells. MET-specific siRNA was intro-
duced into PC-9/Met cells, and nuclear enzymes were extracted from the PC-9/Met cells that contained topo I. The PC-9/Met 
cells in which MET had been down-regulated had lower topo I activity than did the untreated PC-9/Met cells. D, The results of 
the WST-1 assay of cell-growth inhibition by SN-38. The PC-9/Met cells were more sensitive to SN-38 than the PC-9 cells, and 
the sensitivity of cells treated with MET siRNA was reduced. The points represent the means of data generated from at least 
three experiments performed in triplicate. Bars, SD. PC-9, PC-9/Met, PC-9/Met siRNA. topo I, topoisomerase I; siRNA, small 
interfering RNA, SN-38, 7-ethyl-10-hydroxy-camptothecin; con, control; scr, scramble.
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The major limitation of this study is that it did not 
examine whether gefitinib-resistant cells whose resistance 
is mediated by other mechanisms besides MET amplifica-
tion (for example, by the T790M mutation or insulin-like 
growth factor receptor expression), have increased sensitiv-
ity to SN-38, similar to the PC-9/Met cells with the MET 
amplification. To our knowledge, no investigators have ever 
assessed the sensitivity of cell lines with a T790M muta-
tion or IGF-R amplification to SN-38. Furthermore, no 
other cytotoxic agents were assessed, except in the prelimi-
nary experiments. Additional studies of such agents will be 
needed to determine whether there are similar effects, or 
whether the increased sensitivity is specific to SN-38.
In conclusion, the results of this study showed that 
the increased topo I activity induced by MET signaling in 
a gefitinib-resistant cell line resulted in increased sensitiv-
ity of human cancer cells to SN-38. In addition to treatment 
approaches with involving MET-TKIs, we believe that topo I 
inhibitors have the potential to overcome MET-amplification–
mediated resistance to EGFR-TKIs.
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FIGURE 4. A, Cell extracts from PC-9 cells and PC-9/Met cells were prepared after the cells were cultured with HGF (20 ng/
ml) for 30 minutes and 60 minutes, after serum starvation for 24 hours. HGF stimulation induced MET phosphorylation in both 
cell lines. Nuclear extracts containing the topo I enzyme were prepared after 6 hours, 12 hours, and 24 hours of HGF stimula-
tion, and the topo I protein expression level in both PC-9 and PC-9/Met cells was increased after HGF stimulation. The data are 
expressed as the means ± SD from three experiments, *p < 0.05 versus control. B, HGF increased the sensitivity of PC-9 and 
PC-9/Met cells to SN-38. Tumor cells at concentration of 2 × 104 cells/well were incubated in RPMI medium supplemented with 
0.1% fetal bovine serum overnight. HGF (20 ng/ml) was added to the cultures of tumor cells for 4 hours. Increasing concentra-
tions of SN-38 were added to the each well, and the incubation was continued for a further 24 hours. Then, the cell growth 
was determined by the water soluble tetrazolium salt-1 assay. HGF, hepatocyte growth factor; topo I, topoisomerase 1.
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